FocalTherics (NASDAQ:FOCL) Issues Earnings Results, Misses Expectations By $0.19 EPS

FocalTherics (NASDAQ:FOCL) issued its quarterly earnings results on Friday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19), FiscalAI reports. The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.

FocalTherics Trading Up 2.8%

NASDAQ FOCL opened at $4.76 on Friday. The firm has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The stock’s 50 day simple moving average is $5.39. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99.

Institutional Trading of FocalTherics

Several institutional investors have recently made changes to their positions in FOCL. Flax Pond Capital LLC bought a new stake in shares of FocalTherics in the 4th quarter worth about $2,623,000. Leonteq Securities AG acquired a new stake in FocalTherics in the 4th quarter worth approximately $313,000. Rock Springs Capital Management LP lifted its position in FocalTherics by 7.1% during the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after acquiring an additional 91,500 shares during the last quarter. Kovack Advisors Inc. acquired a new stake in FocalTherics in the 4th quarter valued at approximately $53,000. Finally, Lido Advisors LLC bought a new position in FocalTherics in the first quarter worth $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on FOCL. Mizuho set a $15.00 target price on FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research note on Friday. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, FocalTherics presently has an average rating of “Hold” and a consensus target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.